The College of American Pathologists (CAP) defines analytic validity as a test's ability to accurately measure the analyte of interest.
3 In the context of genomic testing using nextgeneration sequencing (NGS), analytic validation of every potential variant (e.g., single nucleotide variants, insertion/deletions, copy number variants, structural chromosomal rearrangements) is not feasible. Therefore, professional guidelines recommend that NGS test validation assures the accuracy of the entire pathway for different types of variants rather than all specific variants (Aziz et al., 2014; Rehm et al., 2013) . Currently, there is an FDA-cleared instrument and reagents, but at this time there is no approved test kit for whole genome sequencing (FDA, 2013) . Of note, using present-day NGS technologies, we cannot fully sequence the exome or genome because of an inability to generate high-quality data for regions of high GC content (e.g., 5' end of the gene) and for pseudogenes or repetitive regions. Anticipated technology advancements should provide more complete coverage of the exome or genome in the future.
During test validation, reference materials are used to determine the false negative, false positive, and accuracy rates. Only recently have the National Institute of Standards and Technology 4 and the Centers for Disease Control and Prevention focused on reference material for NGS. Quality management should be applied to NGS testing as with any clinical test. Quality control measures should determine whether each sample in each run is acceptable. Proficiency testing is required by the Clinical Laboratory Improvement Amendments (CLIA) regulation for any clinical test. The CAP has developed proficiency testing to assess both the sequence data generation (commonly referred to as "wet bench") and the analytical (commonly referred to as the "dry bench") components of NGS testing. In addition, an NGS accreditation checklist for CLIA accreditation of laboratories has been developed by CAP and is currently in use by laboratories accredited through CAP.
The greatest difficulty in demonstrating analytic validity of an NGS-based test is the interpretation of sequencing data to define the pathogenicity of a variant. Analysis of a genome or exome can take up to 50 hours (Brownstein et al., 2014) . Laboratory professionals use public and private databases, sequence analysis programs, clinical correlations, and other resources to predict pathogenicity of variants. The American College of Medical Genetics and Genomics and the Association for Molecular Pathology are developing standards and guidelines for the interpretation of sequence variants, but without access to clinical quality, evidence-based genomic databases, genomic test interpretation will continue to rely heavily on professional judgment.
In summary, some of the key policy issues in analytic validity of NGS tests are as follows:
1. Development of standards for NGS data filtering and analysis; 2. Availability of well-annotated reference materials for controls and validation; 3. Access to clinical quality, evidence-based genomic databases; and 4. Evidence gaps in phenotype-genotype correlation.
